BMS-303141
BMS-303141 (CAS 943962-47-8) is a small molecule inhibitor targeting ATP-citrate lyase (ACL), a cytoplasmic enzyme involved in converting citrate to acetyl-CoA, the essential precursor for de novo fatty acid and cholesterol biosynthesis. It inhibits ACL activity with an IC50 of 0.13 μM (0.94 μM for human ACL). In vitro studies using HepG2 cells show suppression of lipid synthesis (IC50 ~8 μM) without cytotoxicity up to 50 μM. In mouse models, oral administration of BMS-303141 reduces plasma triglyceride, cholesterol, and glucose levels, and restricts weight gain, highlighting its relevance for studying dyslipidemia, obesity, and metabolic disorders.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 424.3 |
| Cas No. | 943962-47-8 |
| Formula | C19H15Cl2NO4S |
| Solubility | ≥21.2 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| Chemical Name | 3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide |
| SDF | Download SDF |
| Canonical SMILES | COC1=C(NS(C2=CC(Cl)=CC(Cl)=C2O)(=O)=O)C=C(C3=CC=CC=C3)C=C1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
HepG2 cells |
|
Preparation method |
The solubility of this compound in DMSO is > 21.2 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
8 μM; 6 hrs |
|
Applications |
In HepG2 cells, BMS-303141 inhibited total lipid synthesis with an IC50 value of 8 μM. Moreover, BMS-303141 showed no cytotoxicity up to 50 μM. |
| Animal experiment [1]: | |
|
Animal models |
High-fat fed mice |
|
Dosage form |
10 and 100 mg/kg; p.o. |
|
Applications |
In high-fat fed mice, BMS-303141 modestly reduced both plasma cholesterol and triglyceride 20 days after treatment. In addition, fasting plasma glucose started to decrease from day 7 to completion of the study. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Li JJ, Wang H, Tino JA, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett, 2007, 17(11): 3208-3211. | |
Quality Control & MSDS
- View current batch:
Chemical structure
